SGEN - Bristol Myers Squibb Further Diversifies Oncology Portfolio With Mega $8.4B Deal | Benzinga
SystImmune and Bristol Myers Squibb & Co (NYSE: BMY) announced an exclusive license and collaboration agreement for SystImmune's BL-B01D1, a potentially first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC).
BL-B01D1 has the potential to treat patients with lung and breast cancer, with opportunities to expand into additional tumor types.
SystImmune will be solely responsible for development, commercialization, and manufacturing in Mainland China and for manufacturing certain drug supplies outside of Mainland China.
Bristol Myers Squibb will assume sole responsibility for development and commercialization in the rest of the world.
Bristol Myers will pay SystImmune up to $8.4 billion for the rights, including an $800 million upfront payment to SystImmune and as much as $500 million ...